Abilify Discmelt Launching At 19% Premium To Regular Tablets
This article was originally published in The Pink Sheet Daily
Bristol/Otsuka’s aripiprazole is the third antipsychotic to offer a quick-dissolving version.
You may also be interested in...
Bristol/Somerset’s product avoids MAOI-class dietary restrictions at the lowest dose.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.